SONG Xia 1,2,3,4 , LIU Zheng 2,3,4,5 , LIU Yan 1,2,3,4 , LI Siyu 2,3,4,5 , SHI Yuqing 1,2,3,4 , DIAO Sha 2,3,4 , LIU Dan 2,3,4 , ZOU Kun 2,3,4 , LU Runxin 2,3,4 , ZENG Linan 2,3,4 , ZHANG Aimin 6 , XIAO Hongjie 6 , ZHANG Lingli 2,3,4,7
  • 1. West China School of Pharmacy, Sichuan University, Chengdu 610041, P. R. China;
  • 2. Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University; Children’s Medicine Key Laboratory of Sichuan Province, Chengdu 610041, P. R. China;
  • 3. NMPA Key Laboratory for Technical Research on Drug Products in vitro and in vivo Correlation, Chengdu 610041, P. R. China;
  • 4. Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu 610041, P. R. China;
  • 5. West China School of Medicine, Sichuan University, Chengdu 610041, P. R. China;
  • 6. Medical Instrument Management Center, National Health Commission of the People’s Republic of China, Beijing 100044, P. R. China;
  • 7. Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
ZHANG Lingli, Email: zhanglingli@scu.edu.cn
Neoplasms; Guideline; Consensus; Essential medicines
10.7507/1672-2531.202408164
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To compare the recommended medicines from malignancy guidelines/consensuses with essential medicines from the 2023 World Health Organization Model List of Essential Medicines (WHO-EML) and the 2018 National Essential Medicine List (NEML) in differences and similarities. Methods Ten guideline databases/association websites including Guidelines International Network, and the American Cancer Society, etc. were systematically searched until July 2023. The latest guidelines/consensuses for ten malignant tumors were screened, including lung cancer, liver cancer, stomach cancer, and other cancers. Recommended medicines were extracted from guidelines/consensuses and compared with WHO and Chinese essential medicines. Results A total of 163 guidelines/consensuses were included, extracting 244 recommended medicines, 12 categories, mainly antineoplastic and immunomodulating agents (190 medicines, 10 subcategories). For the 244 recommended medicines, 29.92% (73/244) were included in WHO-EML and 23.36% (57/244) were included in NEML, among which 45 medicines were included both in WHO-EML and NEML, 27 in WHO-EML only, 11 in NEML only, and 161 in neither. Conclusion The number of recommended medicines in WHO-EML/NEML for ten malignancies is low, and the number in NEML is even much lower than that in WHO-EML. When adjusting medicines for malignant tumors in NEML, reference can be made to specific guidelines/consensuses and WHO-EML to ensure timely inclusion of applicable medicines and strengthen the role of essential medicines in meeting basic medical needs and rational use.

Citation： SONG Xia, LIU Zheng, LIU Yan, LI Siyu, SHI Yuqing, DIAO Sha, LIU Dan, ZOU Kun, LU Runxin, ZENG Linan, ZHANG Aimin, XIAO Hongjie, ZHANG Lingli. A comparative study of recommended drugs by guidelines or consensuses for malignant tumors with the World Health Organization model list of essential medicines and the national essential medicines list. Chinese Journal of Evidence-Based Medicine, 2025, 25(5): 526-531. doi: 10.7507/1672-2531.202408164 Copy

Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved

  • Previous Article

    The diagnostic value of lncRNA in tuberculosis: a meta-analysis

  • Next Article

    Efficacy and safety of acupuncture as adjuvant treatment on sepsis related gastrointestinal dysfunction: a meta-analysis